← Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Press Releases
Date | Press release |
---|---|
2025-04-29 06:45:00 | Pfizer Reports Solid First-quarter 2025 Results And Reaffirms 2025 Guidance New york--(business wire)--pfizer inc. (nyse: pfe) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). executive commentary dr. albert bourla, chairman and ceo of pfizer: “we continued to execute with focus and discipline against our strategic priorities, including strengthening our r&d organization and driving improved productivity. with the underlying strength of our business, we believe we can be agile in navigating an uncertain and vol. |
2025-04-26 13:30:00 | Pfizer’s Sasanlimab Combination Significantly Improves Event-free Survival In Bcg-naÏve, High-risk Non-muscle Invasive Bladder Cancer New york--(business wire)--pfizer inc. (nyse: pfe) today announced results from the pivotal phase 3 crest trial of sasanlimab, an investigational anti-pd-1 monoclonal antibody (mab), in combination with standard of care (soc) bacillus calmette-guÉrin (bcg) as induction therapy with or without maintenance in patients with bcg-naÏve, high-risk non-muscle invasive bladder cancer (nmibc). the trial met its primary endpoint of event-free survival (efs) by investigator assessment, demonstrating a cli. |
2025-04-23 16:40:00 | Pfizer Declares Second-quarter 2025 Dividend New york--(business wire)--pfizer inc. (nyse: pfe) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable june 13, 2025, to holders of the common stock of record at the close of business on may 9, 2025. the second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by pfizer. about pfizer: breakthroughs that change patients’ lives at pfizer, we apply science and our global resources to bring t. |
2025-04-23 15:46:00 | Pfizer Advances Bold Vision For Future Of Cancer Care At The Asco 2025 Annual Meeting New york--(business wire)--pfizer inc. (nyse: pfe) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 american society of clinical oncology (asco®) annual meeting, taking place may 30 to june 3 in chicago. data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral presentations and 6 rapid oral presentations, will be presented across pfizer’s key tumor areas, including breast, genitourinary. |
2025-04-16 16:15:00 | Acip Votes To Expand Recommendation For Pfizer’s Rsv Vaccine Abrysvo® To Include Adults Aged 50 To 59 At Increased Risk Of Disease New york--(business wire)--pfizer inc. (nyse: pfe) announced today that the u.s. centers for disease control and prevention’s (cdc) advisory committee on immunization practices (acip) voted to expand its recommendation for the use of respiratory syncytial virus (rsv) vaccines approved for adults 50-59 years of age at increased risk of rsv-associated lower respiratory tract disease (lrtd). this includes abrysvo® (respiratory syncytial virus vaccine), which in october 2024, the u.s. food and drug. |
2025-04-14 06:45:00 |
|
2025-04-10 11:00:00 |
|
2025-04-04 13:35:00 |
|
2025-04-01 03:00:00 |
|
2025-03-18 10:00:00 |
|
2025-03-12 15:08:00 |
|
2025-03-11 06:45:00 |
|
2025-03-05 11:33:00 |
|
2025-02-24 20:13:00 |
|
2025-02-24 08:33:00 |
|
